Results 51 to 60 of about 1,618 (187)

A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment

BMC Ophthalmology, 2021
Background This article is a case report of pseudoxanthoma elasticum (PXE) which was diagnosed based on significant angioid streaks (AS) with choroidal neovascularization (CNV) and regain normal visual function by intravitreal injection with Conbercept ...
Chaoxiong Cui, Zhanyu Zhou, Yi Zhang, Ding Sun   +3 more
doaj   +1 more source

Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

Acta Ophthalmologica, Volume 104, Issue 1, Page e1-e17, February 2026.
Abstract Purpose Retinopathy of prematurity (ROP) is a major cause of childhood blindness, and selecting the optimal treatment between anti‐vascular endothelial growth factor (anti‐VEGF) and laser therapy is crucial. Understanding their impact on key outcomes, particularly mortality, is essential for informed clinical decision‐making.
Wei‐De Wang, Ya‐Hsin Yao, Chiao‐Hsin Lan, Shih‐Heng Hung, Ta‐Hsin Tsung, Yann‐Guang Chen, Da‐Wen Lu, Jiann‐Torng Chen, Ke‐Hung Chien, Shu‐I Pao, Wei‐Ting Yen   +10 more
wiley   +1 more source

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study

BMC Ophthalmology, 2018
Background Macular neovascular diseases can cause severe vision loss. A newly approved anti—VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of ...
Jin Jing, Shen Yinchen, Chen Xia, Wang Jing, Chen Chong, Xu Xun, Huang Hengye, Liu Kun   +7 more
doaj   +1 more source

Profile of conbercept in the treatment of neovascular age-related macular degeneration

Drug Design, Development and Therapy, 2015
In developed countries, age-related macular degeneration (AMD) is the leading cause of irreversible blindness in individuals over the age of 65 years. Vascular endothelial growth factor (VEGF) plays a vital role in the formation of neovascular AMD.
Xiaodong Sun, Xinmin Lu
openalex   +4 more sources

Continuous Suppression of Pathological Retinal and Choroidal Neovascularization in Cynomolgus Monkeys via Noninvasive Ophthalmic Delivery of a Novel Anti‐VEGFA Nanobody and Proprietary Penetratin Analog Formulation

Advanced Science, Volume 13, Issue 1, 5 January 2026.
Pathological retinal/choroidal neovascularization drives vision loss in DR and AMD. Current anti‐VEGF injections, while effective, require invasive, frequent administration. Pene/LQ015, is developed a novel topical anti‐VEGFA nanobody formulation achieving therapeutic intraocular levels through penetratin analog‐enhanced delivery.
Chong Chen, Min Zhu, Xingyan Fan, Kangjia Lv, Kuan Jiang, Yuchen Zhang, Haoliang Zhang, Xinming Qi, Benjamin TK Lee, Yakun Wan, Gang Wei, Kun Liu, Xun Xu   +12 more
wiley   +1 more source

Driving Innovation: The Impact of National Health Policies on Optometry Research in East Asia

The International Journal of Health Planning and Management, Volume 41, Issue 1, Page 37-46, January 2026.
ABSTRACT This study examines the optometric research landscape in three East Asian countries—China, Japan, and Korea—analysing how research trends align with each country's national health strategies. By evaluating published articles and reviews from national journals between 2006 March 2025, we identify key areas of focus, including paediatric ...
Jihye Ahn, Moonsung Choi
wiley   +1 more source

Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study

Journal of International Medical Research, 2020
Objective This study assessed the efficacy of conbercept for patients with non-proliferative diabetic retinopathy (NPDR). Methods In this retrospective clinical study, 54 patients with NPDR (54 eyes) were treated with intravitreal injection of conbercept
Jing Wang, Peng-Fei Jiang, Min Liu, Ming-Rong Kou, Jia-Ying Lei, Xiao-Ting Yu, Ying Zhao, Hong Wang, Lin-Na Zhang   +8 more
doaj   +1 more source

Evaluation of short-term intraocular pressure changes after intravitreal injection of Conbercept in patients with diabetic macular edema

Frontiers in Pharmacology, 2022
Background: The study concerning the influence of Conbercept, which is an anti-Vascular endothelial growth factor (VEGF) agent, in intraocular pressure (IOP) spike is limited and warrants further investigation.
Yunyan Hu, Yunkao Zeng, Jing Yang, Xiaomin Zeng, Dan Cao, Biqun Ou, Guanrong Zhang, Liang Zhang, Liang Zhang   +8 more
doaj   +1 more source

Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China

BMC Ophthalmology, 2021
Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study.
Xin Nie, Yulong Wang, Hong Yi, Yanbin Qiao   +3 more
doaj   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source